Bristol-Myers Squibb Company and Seattle Genetics, Inc.

Release Summary

Seattle Genetics and BMS Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS and Opdivo in Hodgkin Lymphoma

Bristol-Myers Squibb Company and Seattle Genetics, Inc.